Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Morepen LaboratoriesNSE:MOREPENLAB +2.57%75 3-Year EBITDA Growth Rate is 22.70% as of Mar. 2026, which is 154% above its 10-year median of 8.95. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 75/100 and a GF Value™ of ₹50.04 (Fairly Valued). The stock has 4 warning signs investors should review. Among 813 Drug Manufacturers companies, Morepen Laboratories ranks better than 72.69% on this metric.
During the past 12 months, Morepen Laboratories's average EBITDA Per Share Growth Rate was -12.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 22.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 4.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 10.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Morepen Laboratories was 98.40% per year. The lowest was -32.00% per year. And the median was 8.95% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Morepen Laboratories 3-Year EBITDA Growth Rate Related Terms
NSE:MOREPENLAB vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 22.70% mean?
Morepen Laboratories (NSE:MOREPENLAB) has a 3-Year EBITDA Growth Rate of 22.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Morepen Laboratories and its competitors. This is 154% above median its historical median of 8.95. According to the industry distribution chart, Morepen Laboratories ranks #222 out of 813 companies in the Drug Manufacturers industry, placing it in the top 27.3%.
Is Morepen Laboratories' 3-Year EBITDA Growth Rate too high?
Morepen Laboratories' current 3-Year EBITDA Growth Rate of 22.70% is 154% above median its 10-year median of 8.95. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.70. Morepen Laboratories' value of 22.70% is 160.9% above this industry median. Based on the distribution chart, Morepen Laboratories ranks #222 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #222 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Morepen Laboratories in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.70. Morepen Laboratories' value of 22.70% is 160.9% above this benchmark. While the company's 10-year median is 8.95 vs. the industry median of 8.70, Morepen Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.70, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current 3-Year EBITDA Growth Rate of 22.70% is 160.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current 3-Year EBITDA Growth Rate is 22.70%, which is 154% above median its own 10-year median of 8.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹50.04, compared to a current price of ₹53.80 — trading 7.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 22.70%, which is 154% above median its 10-year median of 8.95 and 160.9% above the Drug Manufacturers industry median of 8.70. Morepen Laboratories' overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current 3-Year EBITDA Growth Rate is 22.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹53.80 is trading 7.5% above its estimated GF Value™ of ₹50.04.
GuruFocus considers Morepen Laboratories to be Fairly Valued.
Key valuation signals for NSE:MOREPENLAB:
3-Year EBITDA Growth Rate: 22.70% (154% above median its 10-year median of 8.95)
GF Value™: ₹50.04 vs. price of ₹53.80 (7.5% above fair value)
Industry Position: 160.9% above the Drug Manufacturers median (#222 of 813)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
75GF Score
Get the complete analysis for NSE:MOREPENLAB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
